Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias

American Journal of Geriatric Psychiatry

Volumn 22, Issue 6, 2014, Pages 580-586

  Creese, Byron ^a   Ballard, Clive ^a   Aarsland, Dag ^b,c   Londos, Elisabet ^d   Sharp, Sally ^e   Jones, Emma ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

5HTTLPR; Dementia with Lewy bodies; Parkinson disease dementia; Polymorphism; Psychosis; SLC6A4

Indexed keywords

SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN;

AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COGNITIVE DEFECT; COHORT ANALYSIS; COLUMBIA UNIVERSITY SCALE FOR PSYCHOPATHOLOGY IN ALZHEIMER; CONTROLLED STUDY; DELUSION; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HALLUCINATION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NORWAY; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PHENOTYPE; PRESENT BEHAVIOURAL EXAMINATION; PROSPECTIVE STUDY; RISK FACTOR; THE NEUROPSYCHIATRIC INVENTORY; UNITED KINGDOM; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; DELUSIONS; GENETICS; HALLUCINATIONS; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

AGED; CASE-CONTROL STUDIES; DELUSIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HALLUCINATIONS; HUMANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84901634829     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2012.11.001     Document Type: Article

References (38)

1. WorldAlzheimerReport. ExecutiveSummary.pdf (application/pdf Object). Available at: http://www.alz.co.uk/research/files/WorldAlzheimerReport- ExecutiveSummary.pdf. Accessed March 9, 2012
2. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872
3. Aarsland D, Andersen K, Larsen JP, et al: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392
4. Tsuboi Y, Dickson DW: Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? Parkinsonism Relat Disord 2005;11(Suppl 1):S47-S51
5. Ballard CG, O'Brien JT, Swann AG, et al: The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry 2001;62:46-49
6. Aarsland D, Ballard C, Larsen JP, et al: A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536
7. Mosimann UP, Rowan EN, Partington CE, et al: Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry 2006;14:153-160
8. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
9. Hamilton JM, Landy KM, Salmon DP, et al: Early visuospatial deficits predict the occurrence of visual hallucinations in autopsyconfirmed dementia with Lewy Bodies. Am J Geriatr Psychiatry 2012;20:773-781
10. Ballard C, Holmes C, McKeith I, et al: Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999;156:1039-1045
11. Del Ser T, McKeith I, Anand R, et al: Dementia with lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15:1034-1045
12. Aarsland D, Cummings JL, Larsen JP: Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001;16:184-191
13. Lanctot KL, Herrmann N, Mazzotta P: Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2001;13:5-21
14. Cheng AVT, Ferrier IN, Morris CM, et al: Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 1991;106:50-55
15. Perry EK, Marshall E, Kerwin J, et al: Evidence of a monoaminergic- cholinergic imbalance related to visual hallucinations in Lewy Body Dementia. J Neurochem 1990;55:1454-1456
16. Huot P, Johnston TH, Darr T, et al: Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010;25:1399-1408
17. Ballanger B, Strafella AP, van Eimeren T, et al: Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010;67:416-421
18. Ballard C, Piggott M, Johnson M, et al: Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-876
19. De Michele-Sweet MA, Sweet RA: Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis 2010;19:761-780
20. Ballard C, Howard R: Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006;7:492-500
21. Collier DA, Stober G, Li T, et al: A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1996;1:453-460
22. Heils A, Teufel A, Petri S, et al: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-2624
23. Lesch K, Bengel D, Heils A, et al: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531
24. Quaranta D, Bizzarro A, Marra C, et al: Psychotic symptoms in Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J Alzheimers Dis 2009;16:173-180
25. Sweet RA, Pollock BG, Sukonick DL, et al: The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr 2001;13:401-409
26. Borroni B, Grassi M, Agosti C, et al: Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 2006;14:343-351
27. Proitsi P, Lupton MK, Reeves SJ, et al: Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging 2012;33:791-803
28. Kiferle L, Ceravolo R, Petrozzi L, et al: Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett 2007;422:228-231
29. Sweet RA, Nimgaonkar VL, Devlin B, et al: Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry 2003;8:383-392
30. Hughes AJ, Daniel SE, Kilford L, et al: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184
31. Jeste DV, Finkel SI: Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8:29-34
32. Cole MG, McCusker J, Voyer P, et al: The course of subsyndromal delirium in older long-term care residents. Am J Geriatr Psychiatry 2013;21:289-296
33. Nagahama Y, Okina T, Suzuki N, et al: Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 2010;133:557-567
34. Aarsland D, Bronnick K, Ehrt U, et al: Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42
35. David SP, Murthy NV, Rabiner EA, et al: A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J Neurosci 2005;25:2586-2590
36. Francis PT, Perry EK: Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord 2007;22:S351-S357
37. Meltzer HY, Mills R, Revell S, et al: Pimavanserin, a serotonin (2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-892
38. Aarsland D, Ballard CG, Halliday G: Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137-145